MIM
BBNX

MetLife Investment Management’s Beta Bionics BBNX Stock Holding History

MetLife Investment Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Hold
22,720
– – ﹤0.01% 2166
2025
Q4 		$692K Hold
22,720
– – ﹤0.01% 1637
2025
Q3 		$451K Buy
22,720
+14,350
+171% +$252K ﹤0.01% 1854
2025
Q2 		$122K Hold
8,370
– – ﹤0.01% 2446
2025
Q1 		$102K Buy
+8,370
New +$156K ﹤0.01% 2515

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's BBNX Position: Q1 2026 in Review

MetLife Investment Management held its Beta Bionics (BBNX) position steady in Q1 2026 at 22,720 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

MetLife Investment Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $692K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • MetLife Investment Management held 22,720 shares of Beta Bionics worth $228K as of Q1 2026.
  • MetLife Investment Management left its Beta Bionics share count unchanged in Q1 2026.
  • Beta Bionics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2166 holding.
  • MetLife Investment Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • MetLife Investment Management's Beta Bionics position peaked at $692K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.